These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 9366322)

  • 21. [Bladder tumor antigen test versus urinary cytology in patients with bladder tumors].
    Gregersen B; Mommsen S; Svanholm H
    Ugeskr Laeger; 1999 Apr; 161(14):2071-3. PubMed ID: 10354792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group.
    Ellis WJ; Blumenstein BA; Ishak LM; Enfield DL
    Urology; 1997 Dec; 50(6):882-7. PubMed ID: 9426718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer.
    D'Hallewin MA; Baert L
    J Urol; 1996 Feb; 155(2):475-6. PubMed ID: 8558639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of screening methods in the detection of bladder cancer.
    Ramakumar S; Bhuiyan J; Besse JA; Roberts SG; Wollan PC; Blute ML; O'Kane DJ
    J Urol; 1999 Feb; 161(2):388-94. PubMed ID: 9915409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
    Schamhart DH; de Reijke TM; van der Poel HG; Witjes JA; de Boer EC; Kurth K; Schalken JA
    Eur Urol; 1998 Aug; 34(2):99-106. PubMed ID: 9693243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
    Abd El Gawad IA; Moussa HS; Nasr MI; El Gemae EH; Masooud AM; Ibrahim IK; El Hifnawy NM
    J Egypt Natl Canc Inst; 2005 Sep; 17(3):193-202. PubMed ID: 16799657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
    Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
    J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic value of voided urine and bladder barbotage cytology in detecting transitional cell carcinoma of the urinary tract.
    Konety BR; Metro MJ; Melham MF; Salup RR
    Urol Int; 1999; 62(1):26-30. PubMed ID: 10436427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of the BTA STAT Test for the diagnosis of bladder cancer.
    Gutiérrez Baños JL; del Henar Rebollo Rodrigo M; Antolín Juárez FM; García BM
    Urology; 2001 Apr; 57(4):685-9. PubMed ID: 11306381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of BTA stat in clinical practice.
    Quek P; Chin CM; Lim PH
    Ann Acad Med Singap; 2002 Mar; 31(2):212-6. PubMed ID: 11957560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of the BTA stat test kit for bladder cancer screening.
    Nasuti JF; Gomella LG; Ismial M; Bibbo M
    Diagn Cytopathol; 1999 Jul; 21(1):27-9. PubMed ID: 10405804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of urinary cytology for detection of bladder cancer.
    Planz B; Jochims E; Deix T; Caspers HP; Jakse G; Boecking A
    Eur J Surg Oncol; 2005 Apr; 31(3):304-8. PubMed ID: 15780568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BTA test is superior to voided urine cytology in detecting malignant bladder tumours.
    Heino A; Aaltomaa S; Ala-Opas M
    Ann Chir Gynaecol; 1999; 88(4):304-7. PubMed ID: 10661829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voided urine versus bladder washing cytology for detection of urothelial carcinoma: which is better?
    Keller AK; Jensen JB
    Scand J Urol; 2017 Aug; 51(4):290-292. PubMed ID: 28398114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer.
    Raitanen MP; Marttila T; Kaasinen E; Rintala E; Aine R; Tammela TL
    J Urol; 2000 Jun; 163(6):1689-92. PubMed ID: 10799161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A comparative study of the sensitivity of bladder washing flow cytometry, voided urine cytology and bladder washing cytology in the detection of bladder carcinoma].
    Tachibana M; Jitsukawa S; Tazaki H; Tashiro Y
    Nihon Hinyokika Gakkai Zasshi; 1989 Jul; 80(7):1025-30. PubMed ID: 2607716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Bard BTA-test in the diagnosis of upper urinary tract tumours.
    Jovanovic M; Hadzi-Djokic J; Dzamic Z; Acimovic M
    Acta Chir Iugosl; 2007; 54(4):19-24. PubMed ID: 18595223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of the BTA test in bladder cancer: a multicenter trial. BTA Study Group Japan.
    Miyanaga N; Akaza H; Kameyama S; Hachiya T; Ozono S; Kuroda M; Koga H; Koiso K
    Int J Urol; 1997 Nov; 4(6):557-60. PubMed ID: 9477183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.